HR Execs on the Move

Chimerix

www.chimerix.com

 
Chimerix is a biopharmaceutical company dedicated to discovering, developing and commercializing medicines that improve outcomes for immunocompromised patients. Chimerix`s proprietary lipid conjugate technology has produced brincidofovir (BCV, CMX001); CMX157, which was licensed to ContraVir Pharmaceuticals; and earlier-stage clinical candidates. Chimerix recently announced a new clinical candidate, CMX521, for the treatment and/or prevention of norovirus.
  • Number of Employees: 100-250
  • Annual Revenue: $0-1 Million
  • www.chimerix.com
  • 2505 Meridian Parkway Suite 100
    Durham, NC USA 27713
  • Phone: 919.806.1074

Executives

Name Title Contact Details
Mike Andriole
President and Chief Executive Officer Profile

Similar Companies

Comfort Medical

You will find the best source for major brands and most types of catheter and ostomy supplies at Comfort Medical. Free Home Delivery 800-700-4246

Pharmacyvillage.com

Pharmacyvillage.com is a Norman, OK-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Argentis Pharmaceuticals

arGentis™ Pharmaceuticals, LLC is a private TN based pharmaceutical company with a mid-stage Orphan Drug treatment (ARG201) for late stage diffuse systemic scleroderma (dcSSc). The company is seeking capital or a partner to complete a Pivotal Clinical Trial which will enable obtaining marketing approval in the EU. The Company has a genotype marker (ROT1) that predicts patient response to treatment by oral tolerance for treatments like ARG201 for dcSSc. Furthermore, arGentis™ has a treatment for Rheumatoid arthritis (ARG301) that is in a Phase I Clinical Trial in the US.

Provider Meds

Provider Meds is a Grapevine, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Everest Medicines

Everest Medicines is dedicated to its mission of developing and commercializing novel transformative pharmaceutical therapies for patients in mainland China and other Asian territories. We strive to be the partner of choice for innovative companies around the world with products that address critical unmet medical needs for patients in Greater China and have a high probability of market approval. The Everest Medicines team has deep expertise and extensive track record of high quality clinical development, regulatory affairs, CMC, business development and operations both in China and with leading global pharmaceutical companies. The company`s Series A round was led by C-Bridge Capital, a top-tier China healthcare private equity firm, with US $800 million under management.